The amount of weight loss achieved with Orlistat varies, with clinical trials over a one year period showing between 35% and 55% of subjects decreasing body mass by 5%, and 15% to 25% achieving at least 10% decrease
PA: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing original draft, Writing review and editing, Resources
In terms of tolerability, tirzepatide generally causes fewer gastrointestinal side effects, making it a better option for those sensitive to nausea, while Semaglutide GLP-1 may cause mild to moderate gastrointestinal issues like nausea and diarrhea, which usually subside over time
Patients should be prepared for potential side effects of semaglutide, including nausea, diarrhea, or vomiting, particularly during the initial weeks of treatment